AE Management With IO-TKI and IO-IO in RCC

Opinion
Video

Martin H. Voss, MD, outlines adverse events encountered with different IO-TKI and IO-IO combination regimens in RCC and discusses the importance of open communication with patients.

Video content above is prompted by the following question:

  • What are the most significant adverse events seen with different IO-TKI and IO-IO combination regimens used in renal cell carcinoma (RCC)?
Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content